Aprea Therapeutics downgraded by Morgan Stanley with a new price target

8/13/21 5:08:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley downgraded Aprea Therapeutics from Equal-Weight to Underweight and set a new price target of $3.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APRE

Date	Price Target	Rating	Analyst
8/20/2021		Neutral → Underweight	JP Morgan
8/16/2021		Buy → Hold	Berenberg
8/16/2021	$6.00 → $4.00	Neutral	HC Wainwright & Co.
8/13/2021	$6.00 → $5.00	Sector Perform	RBC Capital
8/13/2021	$5.00 → $3.00	Equal-Weight → Underweight	Morgan Stanley